Skip to main content

Texas Biologics logo

☰

  • Home
  • About
    • Overview
    • What are Biologics?
    • Executive Committee
    • News
  • Research
    • Our Approach
    • Current Projects
    • Core Facilities
    • Advanced Protein Therapeutics Core
  • Programs
    • Pilot Grants
    • Core Facility Support
    • Clinical Trials Unit
    • Biology & Machine Learning
  • Commercialization
    • Therapeutics Pipeline
    • Technology Partnering
    • Commercialization Partners
    • Resources for Faculty and Students
  • Get Involved
    • Partner with Us
    • Prospective Students
    • Giving
    • Contact
  • Events
  • Home
  • About
    • Overview
    • What are Biologics?
    • Executive Committee
    • News
  • Research
    • Our Approach
    • Current Projects
    • Core Facilities
    • Advanced Protein Therapeutics Core
  • Programs
    • Pilot Grants
    • Core Facility Support
    • Clinical Trials Unit
    • Biology & Machine Learning
  • Commercialization
    • Therapeutics Pipeline
    • Technology Partnering
    • Commercialization Partners
    • Resources for Faculty and Students
  • Get Involved
    • Partner with Us
    • Prospective Students
    • Giving
    • Contact
  • Events

↑

About

About

  • Overview
  • What are Biologics?
  • Executive Committee
  • News
    • In the Media

News

Research Identifies Key Antibodies for Development of Broadly Protective Norovirus Vaccine

Details
March 06, 2025
  • https://news.utexas.edu/2025/03/06/research-identifies-key-antibodies-for-development-of-broadly-protective-norovirus-vaccine/

 

 

UT Austin logo

©

The University of Texas at Austin | Privacy Policy | Web Accessibility

Cockrell School of Engineering
College of Natural Sciences 
Dell Medical School
Resources
  • Contact Us
  • News

Give